Pharmaceutical composition comprising a sulfonylurea drug and preparation method thereof

1. A pharmaceutical composition for injection administration, comprising a sulfonylurea drug, a cyclodextrin and an additive;

wherein said cyclodextrin is 2-hydroxypropyl-β-cyclodextrin and said additive is selected from sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, and meglumine.

2. The pharmaceutical composition according to claim 1 ,

wherein the pharmaceutical composition has a weight ratio of said sulfonylurea drug to said additive of 1:0.5˜100; and

wherein the pharmaceutical composition has a weight ratio of said sulfonylurea drug to said cyclodextrin of 1:25˜1000.

3. The pharmaceutical composition according to claim 2 , wherein the pharmaceutical composition has a weight ratio of said sulfonylurea drug to said additive of 1:1˜100.

4. The pharmaceutical composition according to claim 2 , wherein the pharmaceutical composition has a weight ratio of said sulfonylurea drug to said cyclodextrin of 1:50˜1000.

5. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition has a weight ratio of said sulfonylurea drug:said additive:said cyclodextrin of 1:0.05˜100:0.2˜1000.

6. The pharmaceutical composition according to claim 1 , wherein said sulfonylurea drug is selected from glibenclamide, gliclazide, glipizide, gliquidone, glibornuride, glimepiride, glisoxepide, acetohexamide, glycyclamide, glisamuride, glisentide, glisolamide, glyoctamide, chlorpropamide, tolazamide, tolbutamidum, repaglinide and nateglinide.

7. The pharmaceutical composition according to claim 1 , further comprising glucose, sodium chloride, a lyophilization additive, a pH regulator and/or water.

8. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is an injectable solution or a powder injection.

9. The pharmaceutical composition according to claim 8 , wherein the pharmaceutical composition is an aqueous injectable solution.

10. The pharmaceutical composition according to claim 9 , wherein one or more of said following is satisfied:

a) said pharmaceutical composition comprises an additive at a concentration of 0.01˜0.5% (w/v), said cyclodextrin at a concentration of 0.5˜10% (w/v), a sulfonylurea drug at a concentration of less than or equal to the saturation concentration of said sulfonylurea drug in said injectable solution;

b) said pharmaceutical composition comprises an additive at a concentration of 1˜10% (w/v), said cyclodextrin at a concentration of 1˜30% (w/v), a sulfonylurea drug at a concentration of less than or equal to the saturation concentration of said sulfonylurea drug in said injectable solution.

11. The pharmaceutical composition according to claim 8 , said pharmaceutical composition has a pH of 5˜11.

12. A method for preparing the pharmaceutical composition according to claim 1 , comprising following steps:

a) dissolving the additive and the cyclodextrin in a solvent;

b) adding the sulfonylurea drug into the product of step a), mixing by stirring;

c) optionally, adding a lyophilization additive into the product of step b), and adjusting pH;

d) subjecting the product of step b) or step c) to sterilization,

optionally, drying the product of step d) to obtain the composition.

13. A method for the therapeutic treatment of encephaledema in acute stroke, traumatic brain injury, or in spinal cord injury, and of type I diabetes or type II diabetes, comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition according to claim 1 ;

wherein said sulfonylurea drug is glibenclamide;

wherein said cyclodextrin is 2-hydroxypropyl-β-cyclodextrin.

14. The pharmaceutical composition according to claim 1 , wherein said additive is sodium hydrogen carbonate and/or sodium hydroxide.

15. The pharmaceutical composition according to claim 1 , wherein said additive is sodium carbonate.

16. The pharmaceutical composition according to claim 1 , wherein said additive is meglumine.